The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 12, 2012
Filed:
Sep. 18, 2007
John J. Baldwin, Gwynedd Valley, PA (US);
David A. Claremon, Maple Glen, PA (US);
Colin M. Tice, Ambler, PA (US);
Salvacion Cacatian, Blue Bell, PA (US);
Lawrence W. Dillard, Yardley, PA (US);
Alexey V. Ishchenko, Somerville, MA (US);
Jing Yuan, Lansdale, PA (US);
Zhenrong Xu, Horsham, PA (US);
Gerard Mcgeehan, Garnet Valley, PA (US);
Wei Zhao, Eagleville, PA (US);
Robert D. Simpson, Wilmington, DE (US);
Suresh B. Singh, Kendall Park, NJ (US);
Lanqi Jia, Horsham, PA (US);
Patrick T. Flaherty, Pittsburgh, PA (US);
John J. Baldwin, Gwynedd Valley, PA (US);
David A. Claremon, Maple Glen, PA (US);
Colin M. Tice, Ambler, PA (US);
Salvacion Cacatian, Blue Bell, PA (US);
Lawrence W. Dillard, Yardley, PA (US);
Alexey V. Ishchenko, Somerville, MA (US);
Jing Yuan, Lansdale, PA (US);
Zhenrong Xu, Horsham, PA (US);
Gerard McGeehan, Garnet Valley, PA (US);
Wei Zhao, Eagleville, PA (US);
Robert D. Simpson, Wilmington, DE (US);
Suresh B. Singh, Kendall Park, NJ (US);
Lanqi Jia, Horsham, PA (US);
Patrick T. Flaherty, Pittsburgh, PA (US);
Vitae Pharmaceuticals, Inc., Fort Washington, PA (US);
Abstract
The present invention is directed to aspartic protease inhibitors represented by the following structural formula (I), or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I). Methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using these aspartic protease inhibitors are also disclosed.